INmune Bio Inc. (INMB) Discusses MissionEB Phase III Trial and CORDStrom as a Disease-Modifying Therapy for RDEB Transcript
Source: SeekingAlpha
2026-02-27 00:07:50 ET
INmune Bio Inc. (INMB) Discusses MissionEB Phase III Trial and CORDStrom as a Disease-Modifying Therapy for RDEB February 26, 2026 1:00 PM EST...
Read the full article on Seeking Alpha
For further details see:
INmune Bio Inc. (INMB) Discusses MissionEB Phase III Trial and CORDStrom as a Disease-Modifying Therapy for RDEB Transcript
INmune Bio Inc.
NASDAQ: INMB
INMB Trading
-5.44% G/L:
$1.565 Last:
299,531 Volume:
$1.66 Open:
INMB Latest News
May 15, 2026 08:00:00 am
INmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro(TM) PlatformMay 14, 2026 08:00:00 am
INmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer's DiseaseINMB Stock Data
$100,001,939
20,608,626
3.69%
19
N/A
Biotechnology & Life Sciences
Healthcare
US
Boca Raton
